The estimated Net Worth of Robert S Breuil is at least 1.34 百万$ dollars as of 14 March 2023. Mr Breuil owns over 5,000 units of Graybug Vision stock worth over 901,170$ and over the last 9 years he sold GRAY stock worth over 0$. In addition, he makes 441,076$ as Chief Financial Officer at Graybug Vision.
Mr has made over 13 trades of the Graybug Vision stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of GRAY stock worth 27,500$ on 14 March 2023.
The largest trade he's ever made was exercising 121,217 units of Graybug Vision stock on 3 March 2023 worth over 666,694$. On average, Mr trades about 11,382 units every 73 days since 2015. As of 14 March 2023 he still owns at least 163,849 units of Graybug Vision stock.
You can see the complete history of Mr Breuil stock trades at the bottom of the page.
Robert S. Breuil is the Chief Financial Officer at Graybug Vision.
As the Chief Financial Officer of Graybug Vision, the total compensation of Mr Breuil at Graybug Vision is 441,076$. There are 3 executives at Graybug Vision getting paid more, with Dr. Frederic Guerard Pharm.D. having the highest compensation of 931,025$.
Mr Breuil is 59, he's been the Chief Financial Officer of Graybug Vision since . There are 4 older and 3 younger executives at Graybug Vision. The oldest executive at Graybug Vision, Inc. is Dr. Gerald D. Cagle Ph.D., 77, who is the Sr. Advisor, Head of Bus. Devel. & Director.
Robert's mailing address filed with the SEC is C/O GRAYBUG VISION, INC., 274 REDWOOD SHORES PARKWAY, PO BOX 144, REDWOOD CITY, CA, 94065.
Over the last 4 years, insiders at Graybug Vision have traded over 0$ worth of Graybug Vision stock and bought 2,393,750 units worth 38,300,000$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、James E Deerfield Mgmt Hif,...、Frederic Guerard. On average, Graybug Vision executives and independent directors trade stock every 35 days with the average trade being worth of 720,841$. The most recent stock trade was executed by Robert S Breuil on 14 March 2023, trading 5,000 units of GRAY stock currently worth 27,500$.
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Graybug Vision executives and other stock owners filed with the SEC include: